Bio
Dr. Thiago Almeida Pereira graduated from Federal University of Espírito Santo (Vitória, ES, Brazil) in 2008 with a Bachelor’s of Science in Biology. During this time, Dr. Pereira joined the Human Genetics and Molecular Biology Center and investigated the role of TP53 Ser249 mutation in liver cirrhosis and Hepatocellular carcinoma and evaluated if aflatoxin contamination was associated with liver cancer in Espírito Santo State, Brazil. In 2009, Dr. Pereira started his graduate work at Federal University of Espírito Santo (Vitória, ES, Brazil) and Duke University (Durham, NC, USA) where he investigated the role of the Hedgehog pathway in viral hepatitis B and C and hepatocellular carcinoma, under supervision of Prof. Fausto E L Pereira and Prof. Anna Mae Diehl. After defending his master with thesis in infectious diseases in 2011, Dr. Pereira joined the PhD program in Pathology at Federal University of Bahia (Salvador, BA, Brazil), Oswaldo Cruz Foundation (Salvador,BA, Brazil) and Duke University (Durham, NC, USA). Dr. Pereira investigated the role of hedgehog pathway in human and experimental schistosomiasis mansoni under guidance of Prof. Zilton A. Andrade, Prof. José Roberto Lambertucci and Prof. Anna Mae Diehl. In 2016, Dr. Pereira joined Dr. Tom Wynn’s lab at the Immunopathogenesis section of the Laboratory of Parasitic Diseases of the National Institute of Allergy and Infectious Diseases as a postdoctoral fellow. His research focused on fibrosis pathogenesis, identifying key signaling pathways for therapeutic intervention, and biomarker discovery. To further dissect the role of the Hedgehog pathway in fibrosis, regeneration, and cancer, Dr. Pereira joined Professor Philip Beachy's lab at Stanford University School of Medicine in 2018 as a postdoctoral fellow. Dr. Pereira is currently an Instructor at The Institute for Stem Cell Biology and Regenerative Medicine at Stanford University School of Medicine where he conducts research on liver fibrosis and carcinogenesis focusing on schistosomiasis, non-alcoholic fatty liver disease, hepatocellular carcinoma, and hedgehog signaling.
